EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

Taylor E Woo, Igor Stukalin, Philip Q Ding iD, Siddhartha Goutam iD, Michael Sander iD, Benjamin Ewanchuk iD, Winson Y Cheung, Daniel Y C Heng, Tina Cheng iD

Current Oncology · 2023

DOI: 10.3390/curroncol30100646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Taylor E Woo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Dermatology, University of Calgary, Calgary, AB T2N 1N4, Canada. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups.

Methods

A retrospective, multi-center, provincial cohort database was used to investigate the relationship between age (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsMaleHumansAgedChildAdolescentYoung AdultAdultMiddle AgedAged, 80 and overChild, PreschoolFemaleIpilimumabNivolumabImmune Checkpoint InhibitorsRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsCutaneous Malignant Melanoma

Stichwörter der Autor:innen

ageimmune checkpoint inhibitoripilimumab plus nivolumabmelanomanivolumabolder adultspembrolizumabsurvival

Substanzen

IpilimumabNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Dermatology, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Department of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.

ORCID-Profile: Philip Q Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Tina Cheng

Zitieren

APA

Woo, T. E., Stukalin, I., Ding, P. Q., Goutam, S., Sander, M., Ewanchuk, B., Cheung, W. Y., Heng, D. Y. C., & Cheng, T. (2023). Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma. Current Oncology. https://doi.org/10.3390/curroncol30100646

Vancouver

Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, et al. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma. Current Oncology. 2023. doi:10.3390/curroncol30100646

BibTeX
@article{Woo2023,
  author = {Woo, Taylor E and Stukalin, Igor and Ding, Philip Q and Goutam, Siddhartha and Sander, Michael and Ewanchuk, Benjamin and Cheung, Winson Y and Heng, Daniel Y C and Cheng, Tina},
  title = {Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30100646}
}
Kostenlos starten →